Learn more about whether Catalyst Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Viridian Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The government is next year to offer new single-dose pneumococcal vaccines, as well as adjuvanted influenza vaccines for some elderly people, while increasing the administration fee for young children ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody ...

Soma Gold Corp. (WKN: A2P4DU) (the "Company" or "Soma") is pleased to announce that the Colombian government has issued drill permits for the copper anomaly in the Psyche 2 target area of the Machuca ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Former Liberal MP Dr Katie Allen has died aged 59 surrounded by her family. Her family released a statement via Dr Allen's ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

Daiichi Sankyo begins patient dosing in DESTINY-Endometrial02 phase 3 trial of Enhertu in patients with HER2 expressing endometrial cancer: Tokyo Tuesday, December 23, 2025, 10:00 ...